Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov 16:2:31.
doi: 10.1186/1743-7075-2-31.

Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction

Affiliations

Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction

Jeff S Volek et al. Nutr Metab (Lond). .

Abstract

Metabolic Syndrome (MetS) represents a constellation of markers that indicates a predisposition to diabetes, cardiovascular disease and other pathologic states. The definition and treatment are a matter of current debate and there is not general agreement on a precise definition or, to some extent, whether the designation provides more information than the individual components. We consider here five indicators that are central to most definitions and we provide evidence from the literature that these are precisely the symptoms that respond to reduction in dietary carbohydrate (CHO). Carbohydrate restriction is one of several strategies for reducing body mass but even in the absence of weight loss or in comparison with low fat alternatives, CHO restriction is effective at ameliorating high fasting glucose and insulin, high plasma triglycerides (TAG), low HDL and high blood pressure. In addition, low fat, high CHO diets have long been known to raise TAG, lower HDL and, in the absence of weight loss, may worsen glycemic control. Thus, whereas there are numerous strategies for weight loss, a patient with high BMI and high TAG is likely to benefit most from a regimen that reduces CHO intake. Reviewing the literature, benefits of CHO restriction are seen in normal or overweight individuals, in normal patients who meet the criteria for MetS or in patients with frank diabetes. Moreover, in low fat studies that ameliorate LDL and total cholesterol, controls may do better on the symptoms of MetS. On this basis, we feel that MetS is a meaningful, useful phenomenon and may, in fact, be operationally defined as the set of markers that responds to CHO restriction. Insofar as this is an accurate characterization it is likely the result of the effect of dietary CHO on insulin metabolism. Glucose is the major insulin secretagogue and insulin resistance has been tied to the hyperinsulinemic state or the effect of such a state on lipid metabolism. The conclusion is probably not surprising but has not been explicitly stated before. The known effects of CHO-induced hypertriglyceridemia, the HDL-lowering effect of low fat, high CHO interventions and the obvious improvement in glucose and insulin from CHO restriction should have made this evident. In addition, recent studies suggest that a subset of MetS, the ratio of TAG/HDL, is a good marker for insulin resistance and risk of CVD, and this indicator is reliably reduced by CHO restriction and exacerbated by high CHO intake. Inability to make this connection in the past has probably been due to the fact that individual responses have been studied in isolation as well as to the emphasis of traditional therapeutic approaches on low fat rather than low CHO. We emphasize that MetS is not a disease but a collection of markers. Individual physicians must decide whether high LDL, or other risk factors are more important than the features of MetS in any individual case but if MetS is to be considered it should be recognized that reducing CHO will bring improvement. Response of symptoms to CHO restriction might thus provide a new experimental criterion for MetS in the face of on-going controversy about a useful definition. As a guide to future research, the idea that control of insulin metabolism by CHO intake is, to a first approximation, the underlying mechanism in MetS is a testable hypothesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of features of Metabolic Syndrome on low carbohydrate vs. high carbohydrate diets. Data from reference [45].
Figure 2
Figure 2
Per cent change in response to diet. Low carbohydrate (dark blue 25 % CHO) and low fat diets(light blue: 45 % CHO). Data from Golay, et al. [52].
Figure 3
Figure 3
Effect of carbohydrate on parameters of Metabolic Syndrome. Comparison of 40% CHO (blue) and 55% (red) CHO diets. Data from [54].
Figure 4
Figure 4
Effect of diet on plasma glucose. Mean plasma glucose concentration before (triangles) and after 5 weeks on control diet (yellow circles: (CHO:fat:protein = 55:30:15)) or 5 weeks on lower carbohydrate diet (blue circles: (20:50:30)). Meal points are Breakfast (B), lunch (L) and dinner(D) plus 2 snacks (S1, S2). Data from reference [57].
Figure 5
Figure 5
Changes in cholesterol/HDL for substitution for fat. Fat in the average American diet was substituted with the indicated substances at 10 % of energy. Data from reference [62].
Figure 6
Figure 6
Prevalence of pattern B phenotype as a function of the percentage dietary CHO in men. Data from reference [71].

Similar articles

Cited by

References

    1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi: 10.1016/S0140-6736(05)66378-7. - DOI - PubMed
    1. Grundy SM, Brewer HBJ, Cleeman JI, Smith SCJ, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–438. doi: 10.1161/01.CIR.0000111245.75752.C6. - DOI - PubMed
    1. Grundy SM, Hansen B, Smith SCJ, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol. 2004;24(2):e19–24. doi: 10.1161/01.ATV.0000112379.88385.67. - DOI - PubMed
    1. Tonkin A. The metabolic syndrome -- a growing problem. European Heart Journal Supplements. 2004;6:A37–A42.
    1. Aude YW, Mego P, Mehta JL. Metabolic syndrome: dietary interventions. Curr Opin Cardiol. 2004;19(5):473–479. doi: 10.1097/01.hco.0000134610.68815.05. - DOI - PubMed